ondansetron has been researched along with Tourette Syndrome in 3 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Tourette Syndrome: A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or another medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 7.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 3.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| "Ondansetron dose was 8, 16, and 24 mg/day in the first, second, and third weeks, respectively." | 2.71 | Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study. ( Cohen, D; Laor, N; Ratner, S; Toren, P; Weizman, A, 2005) |
| "Ondansetron treatment was associated with a significant decrease in the severity of tics." | 2.69 | Ondansetron treatment in patients with Tourette's syndrome. ( Cohen, DJ; Laor, N; Toren, P; Weizman, A; Wolmer, L, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toren, P | 2 |
| Weizman, A | 2 |
| Ratner, S | 1 |
| Cohen, D | 1 |
| Laor, N | 2 |
| Rizzo, R | 1 |
| Marino, S | 1 |
| Gulisano, M | 1 |
| Robertson, MM | 1 |
| Cohen, DJ | 1 |
| Wolmer, L | 1 |
2 trials available for ondansetron and Tourette Syndrome
| Article | Year |
|---|---|
Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Child; Double-Blind Method; Female; Humans; Male; Middle Aged; Ondansetron; Place | 2005 |
Ondansetron treatment in patients with Tourette's syndrome.
Topics: Adolescent; Adult; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Ondansetron; Pi | 1999 |
1 other study available for ondansetron and Tourette Syndrome
| Article | Year |
|---|---|
The successful use of ondansetron in a boy with both leukemia and Tourette syndrome.
Topics: Anti-Dyskinesia Agents; Antiemetics; Antineoplastic Agents; Biperiden; Brain; Child; Dose-Response R | 2008 |